Are all skin TRM cells created equal? Beyond excited to share our new paper in Science Magazine, where we show diverse CD8+ TRM use distinct molecular pathways to develop and persist in skin, which we can target to fine-tune the skin-immune landscape🧵👇🏻 science.org/doi/10.1126/sc…

I am very excited to share the final story of my PhD, online now as a pre-print in bioRxiv, where we dissect the opposing effects of antibody-feedback and memory T cell help on recall germinal centers (GCs). 1/n biorxiv.org/content/10.110…

IT’S GREAT TO BE A MICHIGAN WOLVERINE! #GoBlue

Happy to share our recent work let by postdoc verenalink (she/her) published today in Nature Medicine. 👩‍🔬🥳Ketogenic and vegan diet differentially impact human immune system, microbiome and metabolism. (1/7) 🧵👇 nature.com/articles/s4159…

Excited to share our recent work: "#SingleCell Masked Autoencoder: An Accurate and Interpretable Automated Immunophenotyper" scMAE model transforms high-throughput single-cell cytometry, offering a scalable, robust, and precise immunophenotyping tool.E. John Wherry Immune Health

🚨Tumor infiltrating lymphocyte (TIL) therapy is now FDA approved for advanced cutaneous melanoma. A milestone event for cell therapy in solid malignancies.

FDA approves first tumour-infiltrating lymphocyte therapy, bolstering hopes for cell therapies in solid cancers bit.ly/49b0Q4p Iovance’s lifileucel for patients with melanoma is the result of >30 years of research on this cell therapy modality bit.ly/3NldJQE

This is great news for T cell therapies for cancer. nbcnews.com/health/health-…

The Perelman School of Medicine has received a $2.1M grant from PolyBio to expand #longCOVID research. The funding will support studies focusing on SARS-CoV-2 persistence in the gut, in addition to work defining long COVID immune responses. spr.ly/6019X6tEF

Just in time for #AAD2024 - check out our new review on the pathogenesis and treatment of cutaneous T-cell lymphoma Everything from the deep-cut immunology of this rare skin cancer to some amazing clinical pearls from one of the OG CTCL experts Dr. Rook pubmed.ncbi.nlm.nih.gov/38450476/

Excited to see this in Immunity! With Timothy Johnston, Grace Li, Hensley Lab, and E. John Wherry, we show how immune imprinting by mRNA vaccines enhances neutralizing responses to SARS-CoV-2 variants and how variant-specific responses can still emerge. cell.com/immunity/fullt…

Congrats to all the 2024 PD Soros Fellowships fellows and welcome to the fam! Special shoutout to Min Jae Kim for representing Penn Penn Medicine Applications for the 2025 fellowship are now open at pdsoros.org/apply. If you have any questions send me a DM and I'd love to help out

S/o PD Soros Fellowships for sending the best end of semester care package. Forever grateful for the fellowship (and this mountain of candy 🍭)

As finals approach, we sent our 2022 & 2023 #PDSoros Fellows a care package from one of our favorite small businesses, Economy Candy! ❤️🍭🍬

extremely excited to share our new story on the impact of JAK inhibition on responses to immune checkpoint blockade in lung cancer patients! 🧬🧑‍🔬 thread on our main findings 🧵 1/n science.org/doi/10.1126/sc…

Exciting new paper from Divij highlighting the ability to drug the "immunopharmacology" of checkpoint blockade to improve responses in NSCLC. aPD1+transient JAK inhibition. A great collaboration with Andy Minn. Similar work from J.Teijaro scripps …w-science-org.proxy.library.upenn.edu/doi/pdf/10.112…

Awesome opportunity for any young immunologists out there!

Very happy to share this new work on LAG3 and PD1. Has been a long road to (begin to) sort out how LAG3 functions in CD8 T cell exhaustion. Great work by Shin Ngiow and super collaboration (and 2 other great papers) with Vignali Lab and Dario Vignali cell.com/cell/abstract/…

📣📣📣this Monday come meet our residents and learn more about Harvard Derm!! We can’t wait to see you! Happy application season 2024-2025. Register here tinyurl.com/harvardcombine…!! 🥰🤩🥳#derm #dermatology #Match2025